US 9,624,525 B2 · Method for treating pervasive development disorders

Abstract

A method of utilizing the chymotrypsin level of an individual as a measure of the success of neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. A method for determining the efficacy of neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with neuropeptides, peptides, or digestive enzyme administration.

Claims28

Dependent claims

A method for determining if an individual having a Pervasive Developmental Disorder (PDD) and a subnormal level of fecal chymotrypsin has improved after administration of a dose of digestive enzymes;

the method comprising:
a) making a quantitative pre-administration measurement of a symptom of a PDD and measuring a pre-administration level of fecal chymotrypsin in the individual;
b) administering to the individual a dose of digestive enzymes if the individual has a subnormal level of fecal chymotrypsin, wherein the digestive enzymes comprise a protease, an amylase and a lipase;
c) making a quantitative post-administration measurement of the symptom of the PDD and measuring a post-administration level of fecal chymotrypsin in the individual;
and
d) comparing the quantitative post-administration measurement of the symptom of the PDD to a quantitative pre-administration measurement of the symptom of the PDD,
wherein a decrease in the quantitative post-administration measurement of the symptom compared to the quantitative pre-administration of the symptom indicates the PDD has improved.

4 more elements

Dependencies are inferred from the claim text.

Method for treating pervasive development disorders

Life of this patent

Method for treating pervasive development disorders

Life of this patent

Abstract

Claims28